QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Recruiting in Palo Alto (17 mi)
+7 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1 & 2
Waitlist Available
Sponsor: Altor BioScience
No Placebo Group
Trial Summary
What is the purpose of this trial?
This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-801 combined with cisplatin. The purpose of this study is to evaluate the safety, determine the Maximum-Tolerated Dose (MTD), and characterize the pharmacokinetic profile of ALT-801 given with cisplatin in patients who are chemotherapy naïve and have metastatic melanoma that is considered surgically incurable. The anti-tumor responses of ALT-801 with cisplatin will also be assessed in this trial.
Research Team
HW
Hing Wong, PhD
Principal Investigator
Altor BioScience
Eligibility Criteria
Inclusion Criteria
Locally advanced or metastatic melanoma
Measurable
Histologically or cytologically confirmed
See 7 more
Treatment Details
Interventions
- ALT-801 (Immunotherapy)
- Cisplatin (Alkylating agents)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: ALT-801Experimental Treatment2 Interventions
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Northwestern UniversityChicago, IL
Carolinas Medical Center-Brumenthal Cancer CenterCharlotte, NC
University of Iowa Hospitals and ClinicsIowa City, IA
Emory UniversityAtlanta, GA
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Altor BioScience
Lead Sponsor
Trials
18
Patients Recruited
520+
National Cancer Institute (NCI)
Collaborator
Trials
14080
Patients Recruited
41,180,000+